Pharma Firms Reveal Trump Drug Pricing Deals

• Novo Nordisk reduced Ozempic and Wegovy prices from $1,000-$1,350 per month to $350 through TrumpRx, while offering insulin products at $35 per month
• Bristol Myers Squibb agreed to provide blood-thinner Eliquis to Medicaid for free and donate over seven tons of active pharmaceutical ingredient
• Companies including Pfizer, AstraZeneca, and Amgen committed to discounts of 60-85% off list prices through direct-to-patient platforms and TrumpRx.gov

Summary: Trump Administration Secures Drug Pricing Deals with Major Pharma Companies

Key Development:

President Trump secured agreements with 17 major pharmaceutical companies to align U.S. prescription drug prices with those in other developed nations. In exchange, companies receive three-year exemptions from tariffs on drug imports.

Deal Structure:

• Pharmaceutical firms committed to "most-favored-nation" pricing
• Direct-to-consumer sales through new government platform TrumpRx.gov
• Billions of dollars in U.S. investment pledges
• Agreements initiated via letters sent to pharma leaders in January

Major Company Commitments:

Novo Nordisk: Ozempic reduced from $1,000 to $350/month; Wegovy from $1,350 to $350/month; insulin products at $35/month

Pfizer: Up to 85% discounts on select brands including Xeljanz; average 50% savings on primary care treatments

Eli Lilly: Weight-loss drugs capped at $50/month for self-pay patients; Zepbound at $299-$449/month; migraine treatment Emgality at $299

Bristol Myers Squibb: Blockbuster blood thinner Eliquis provided free to Medicaid

Amgen: Cholesterol drug Repatha at $239/month (60-80% off list price)

Other participants: AstraZeneca (up to 80% discounts), J&J, AbbVie, Gilead Sciences, Merck, Roche/Genentech, Novartis, Sanofi, GSK, Boehringer Ingelheim, EMD Serono, and Regeneron

Market Implications:

The deals represent a significant shift in U.S. pharmaceutical pricing policy, potentially reducing healthcare costs for consumers while providing regulatory certainty for manufacturers. The tariff exemptions offer near-term financial relief to pharma companies, though reduced prices may impact revenue streams. The TrumpRx.gov platform creates a new direct-to-consumer distribution channel, potentially disrupting traditional pharmacy benefit managers.